Forecasting The Future: 5 Analyst Projections For G1 Therapeutics
Portfolio Pulse from Benzinga Insights
Five analysts have recently updated their ratings on G1 Therapeutics (NASDAQ:GTHX), showing a predominantly bullish outlook with an average 12-month price target of $11.2, up 17.89% from the previous $9.50. The ratings range from 'Buy' to 'Outperform', with price targets varying significantly from $4.00 to $14.00. G1 Therapeutics, a biopharmaceutical company focused on cancer treatment, has seen a -47.83% decline in revenue growth and faces challenges in market capitalization, net margin, ROE, ROA, and debt management.
February 28, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
G1 Therapeutics has received updated bullish ratings from analysts, with a significant increase in the average price target to $11.2, despite facing revenue decline and financial challenges.
The bullish outlook from analysts, despite G1 Therapeutics' recent revenue decline and financial challenges, suggests a strong belief in the company's long-term potential. The increase in the average price target reflects optimism about the company's future performance, potentially leading to a positive short-term impact on GTHX's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100